Primer: Sirnaomics (2257 HK) - Oct 2025
Sirnaomics is a clinical-stage biopharmaceutical company specializing in the discovery and development of RNA interference (RNAi) therapeutics,...
529 Views
Suzhou Ribo Life Science (瑞博生物) Pre-IPO: Competition Understated
​Suzhou Ribo Life seeks to raise $100 million through Hong Kong listing with CICC and Citi as deal sponsors. We note understate of the competitive...
272 Views
Pre-IPO Suzhou Ribo Life Science - The Strength, the Concerns and the Outlook for the SiRNA Unicorn
​Ribo's delivery technologies drives innovative therapeutics, but valuation fluctuations reflect market's caution on profit model. Future valuation...
425 Views
Hong Kong Connect Flows (December): $10.7bn Inflows Led by Banks
We analyzed the Hong Kong Connect Scheme for December and highlighted flows for CCB, Alibaba, China Mobile, ICBC, ABC, Meituan, Kuaishou, Wuxi...
860 Views
China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji
Out-licensing early-stage pipelines is the worst option. China Biotech at a critical point in verifying business models. CNPGC has other methods to...
578 Views